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ABSTRACT 
 
Synthetic cannabinoids (SC) have been distributed as an alternative to Cannabis marijuana, it is not legal in many 
countries. Cannabinoid receptors and their endogenous ligands termed as the cannabinoid system have been used as 
molecular targets for the treatment of various diseases, including neurodegenerative diseases, neuropathic or 
inflammatory pain, cardiovascular disorders and metabolic syndrome. A lot of study have been done and are 
continuing about anti proliferative effect of SC on many cancers various. We aimed to share our experience the 
effect of synthetic cannabinoid to voiding by evaluating three cases. 
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Introduction 
 
 
Synthetic cannabinoids (SC) have been distributed as 
an alternative to Cannabis marijuana, it is not legal in 
many countries [1]. “Bonzai” is the known name in 
Turkey. SC may lead to more severe toxic effects than 
natural cannabinoids, possibly due to their potent and 
unpredictable actions on endogenous cannabinoid 
receptor systems in the central nervous system at 
animal study [2, 3]. Psychosis, pulmonary toxity, acute 
kidney injury, tachycardia, bradycardia, myocardial 
infarction, autonomic hyperactivity, seizures, euphoria 
and suicidal behavior are known adverse events by SC 
using [4- 10]. We aimed to share our experience the 
effect of synthetic cannabinoid to voiding by 
evaluating three cases. 
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Cases Presentation 
Case-1 
A 22 year old man patient has come to our policlinic 
with poor urinary stream symptom for 1 year. He 
seemed lethargic and him speech was slowly. There is 
no any significant thing in patient’s medical history. 
Physical examination was normal. Penis was 
circumcised and external mea was normal.  Urinalysis 
was clean. Urinary system ultrasound examination was 
done. Bilateral renal parenchyma and pelvis were 
normal. Post voiding residual urine volume was about 
100 cc. We have done uroflowmetry examination. 
Maximum flow rate 8.7 ml/sec and voiding pattern was 
staccato. We have not seen any abnormal finding on 
neurological examination when we have done 
neurology consultation. We have suggested 
urethrocyctoscopy to patient. We have done 
urethrocyctoscopy. Urethra was normal, bladder was 
no trabeculate and capacity was about 500 cc. Bladder 
neck and prostate were normal. After examination, 
when patient woke up, he was very excited and 
aggressive. We have consulted the patient to 
psychiatry. We learned that he takes synthetic 
cannabinoid. We suggest to him to going to 
rehabilitation clinic. Him symptoms has been normal 
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after three months, when he cut using synthetic 
cannabinoid completely. Maximum flow rate 31 ml/ 
sec, average flow rate 20 ml/ sec were on uroflowmetry 
examination. 
Case-2 
A 28 year old man patient has come to our policlinic 
with poor urinary stream, hesitancy and intermittency 
symptoms for 9 months. He seemed euphoric. He said 
the use synthetic cannabinoid regularly for 2 years. He 
has been injured with knife before 2 years ago and 
urethral catheterization was inserted during 
hospitalization. Physical examination was normal. 
Penis was circumcised and external mea was normal. 
Urinalysis was clean. Urinary system ultrasound 
examination was done. Bilateral renal parenchyma and 
pelvis were normal. Prostate volume was 20 cc. Post 
voiding residual urine volume was about 50 cc. We 
have done uroflowmetry examination. Maximum flow 
rate 9.1 ml/sec and voiding pattern was staccato. We 
have not seen any abnormal finding on neurological 
examination when we have done neurology 
consultation. We have done urethrocyctoscopy 
thinking urethral stricture by urethral catheterization 
previously. Urethra was normal, bladder was slightly 
trabeculate and capacity was about 450 cc. Bladder 
neck and prostate were normal. We suggest to him to 
going to rehabilitation clinic. Him symptoms has been 
normal after three months, when he cut using synthetic 
cannabinoid completely. Maximum flow rate 27 
ml/sec, average flow rate 18 ml/sec were on 
uroflowmetry examination. 
Case-3 
A 48 year old man patient has come to our policlinic 
with poor urinary stream, hesitancy and terminal 
dribbling symptoms for 2 years. He seemed worried. 
He said the use synthetic cannabinoid regularly for 2 
years. He was tortured for two years before 30 years 
ago. Physical examination was normal. Penis was 
circumcised and external mea was normal. Prostate 
was felt small and regularly on digital rectal 
examination. Urinalysis was clean. Urinary system 
ultrasound examination was done. Bilateral renal 
parenchyma and pelvis were normal. Prostate volume 
was 25 cc. PSA level was 0,8 ng/dl. Post voiding 
residual urine volume was about 120 cc. We have done 
uroflowmetry examination. Maximum flow rate 7.6 
ml/sec and voiding pattern was staccato. We suggested 
alfa blocker treatment for 1 month. The patient’s 
symptoms continued after one month. We have not 
seen any abnormal finding on neurological 
examination when we have done neurology 
consultation. We have done urethrocyctoscopy. Urethra 
was normal, bladder was slightly trabeculate and 
capacity was about 400 cc. Bladder neck and prostate 
were normal. We suggest to him to going to 
rehabilitation clinic. But the patient has not gone to 
rehabilitation clinic. Him symptoms continue still.   
Discussion and Conclusions 
Cannabinoid is a family of complex chemicals 
molecules. Their actions by binding to and activating 
specific Gα-i protein-coupled receptors named as 
cannabinoid receptor, CB1 (Central receptor) and CB2 
(Peripheral receptor) [11, 12]. CB1 and CB2 have been 
synthesized from mammalian tissues, the main 
difference between them being their tissue expression 
[13]. CB1 receptors mostly presence found in the 
central nervous system, where they mediate 
cannabinoid psychoactive effects [14, 15]. CB1 
receptors are also present in peripheral nerve terminals, 
in extra-neural tissues such as testis, uterus, eye, 
vascular endothelium, spleen and adipocytes [15]. CB2 
receptor expression is mostly restricted to area of B 
lymphocyte [16]. Cannabinoid receptors and their 
endogenous ligands termed as the cannabinoid system 
have been used as molecular targets for the treatment 
of various diseases, including neurodegenerative 
diseases, neuropathic or inflammatory pain, 
cardiovascular disorders and metabolic syndrome [12]. 
A lot of study have been done and are continuing about 
anti proliferative effect of SC on many cancers various 
[17]. 
Our information about SC is limited. All of studies are 
animal study or case reports. This molecule is illegal in 
many countries. Prospective study is impossible. We 
think the voiding dysfunction effect of SC is by 
impacted cannabinoid receptor in peripheral and 
central nerve system. Serotonin uptake velocity 
increase by the time on chronic cannabinoid user 
 Asian Pac. J. Health Sci., 2014; 1(4): 461-464                                         e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Bayar et al ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2014; 1(4): 461-464 
www.apjhs.com      463 
 
patients [18]. Serotonin uptake causes to detrusor 
contractility inhibition, increases bladder capacity and 
urethral closure pressure [19, 20]. Patients’ voiding 
patterns were staccato. We know staccato pattern is 
sign of detrusor sphincter dyssynergia. Bladder 
underactivity and sphincter overactivity are probably 
outcome of chronic cannabinoid using. So, chronic 
cannabinoid using causes voiding dysfunction 
indirectly. All three patients’ symptoms were late 
onset. We think this effect is not related to abuse. 
Because, no one has signed of abuse symptoms and we 
found no one findings of abuse(cardiac, pulmonary or 
kidney dysfunction). We think this effect is related 
regularly using SC. Voiding dysfunction effect is 
unlike other adverse event, it is not abuse effect. 
SC using is very common in many cities. We can see 
patients in emergency department in life threating 
situation like as cardiac or pulmonary dysfunction. 
Voiding dysfunction is may be first symptom except 
behavioral characteristics. Physician must be alert and 
think SC using on unexplained situation for voiding 
dysfunction, particularly young patients.   
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